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Abstract
Bone grafting procedures are performed to treat wounds incurred during wartime trauma, 
accidents, and tumor resections. Endogenous mechanisms of repair are often insufficient to ensure 
integration between host and donor bone and subsequent restoration of function. We investigated 
the role that bone marrow-derived cells play in bone regeneration and sought to increase their 
contributions by functionalizing bone allografts with bioactive lipid coatings. Polymer-coated 
allografts were used to locally deliver the immunomodulatory small molecule FTY720 in tibial 
defects created in rat bone marrow chimeras containing genetically-labeled bone marrow for 
monitoring cell origin and fate. Donor bone marrow contributed significantly to both myeloid and 
osteogenic cells in remodeling tissue surrounding allografts. FTY720 coatings altered the 
phenotype of immune cells two weeks post-injury, which was associated with increased 
vascularization and bone formation surrounding allografts. Consequently, degradable polymer 
coating strategies that deliver small molecule growth factors such as FTY720 represent a novel 
therapeutic strategy for harnessing endogenous bone marrow-derived progenitors and enhancing 
healing in load-bearing bone defects.
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1. Introduction
Bone grafting is the second most common transplant operation after blood, with more than 
500,000 bone grafting procedures in the United States annually and 2.2 million worldwide 
[1]. Autograft usage is the gold standard for bone graft transplant due to its osteoinductive, 
osteoconductive, and osteogenic properties [1–3]. However, autografting procedures may 
lead to donor site complications in as many as 30% of patients and is often insufficient for 
the treatment of massive bone loss such as that suffered during acute trauma and limb 
salvage surgeries [3]. Allograft, or transplantation tissue harvested from a donor, is a viable 
alternative to autograft and constitutes approximately one-third of all bone grafting 
procedures performed in the United States [4]. While use of allografts eliminates the risk of 
donor site morbidity, the risk of disease transmission from donor to patient necessitates the 
need for extensive sterilization procedures that often minimize the osteoinductive and 
osteogenic properties [3,4]. New strategies are needed to restore the lost therapeutic 
properties of allografts to enable adequate integration with host bone and ensure restoration 
of function.
Endogenous cell populations represent a powerful and adaptable tool for improving the host 
regenerative response after injury. Typical stages of bone healing include hematoma 
formation at the fracture site, which leads to the infiltration of myeloid cells (primarily 
neutrophils and monocytes) and the development of granulation tissue and new blood 
vessels. Mesenchymal stem cells (MSCs) then migrate into the fracture site and begin 
proliferating and differentiating into osteoblasts, chondrocytes, and fibroblasts that 
eventually form a callus, ending with growth and remodeling of new bone [5]. Both myeloid 
cells and mesenchymal cells can migrate from adjacent bone marrow and may infiltrate the 
injury site from the blood in response to damaged endothelium and chemotactic cues. The 
precise origin of MSCs and osteoblastic progenitor cells is not well understood despite 
evidence that the blood, bone marrow, and adjacent tissue compartments may serve as 
sources for mesenchymal cells [6]. MSCs serve as both direct and indirect contributors to 
bone repair, directly differentiating into bone-forming cells and secreting 
immunomodulatory factors that condition the injury microenvironment and participate in 
reciprocal signaling with inflammatory cells [5]. Bone marrow-derived monocytes and 
macrophages appear to play multi-faced roles in bone repair, regulating the acute 
inflammatory response [7], contributing to the pool of myeloid-derived pre-osteoclasts [8], 
and secreting factors that enable intramembranous ossification [9]. Osteal macrophages or 
“osteomacs” are present in bone both homeo-statically and after injury and their depletion 
completely eliminates the endosteal bone-forming osteoblast lining [10]. Moreover, the 
desired phenotype of macrophages, whether pro-inflammatory “M1-like” or anti-
inflammatory “M2-like”, and the dynamics of their persistence in tissue after initial injury is 
likely important, but not well understood.
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Regulating the relative contributions of endogenous therapeutic cells from distinct 
compartments is likely critical to improving biomaterial-based therapies for promoting bone 
regeneration. Sphingosine-1-phosphate (S1P) is a bioactive sphingolipid growth factor that 
plays physiological roles in immune cell trafficking [11,12], vascular network formation and 
maturation [13,14], and osteogenic activities [15] and thus represents a likely therapeutic 
target for regulating cell populations within the injury niche. FTY720, a structural analog of 
sphingosine that activates signaling through four of the five known S1P receptors, has 
previously been shown to improve endothelial integrity, promote osteogenesis, and inhibit 
osteoclastogenesis [15–17]. Previous studies in our lab have demonstrated that biomaterial-
based delivery of FTY720 induces angiocrine signaling within the endothelium to recruit 
pro-regenerative cell types such as anti-inflammatory monocytes and pro-angiogenic M2 
macrophages [18,19] that facilitate neovascularization and bone formation [20–22]. 
Encapsulation within poly(lactic-co-glycolic acid) (PLGA) enables sustained release and 
signaling of FTY720 for at least 3 days in vivo and generates gradients that spatially localize 
pro-regenerative responses to peri-implant tissue [12]. S1P signaling also regulates 
reciprocal signaling between osteoblasts and osteoclasts [15], as well as induces platelet-
derived growth factor (PDGF)-BB secretion by monocytic pre-osteoclasts that promotes 
coupling between angiogenesis and osteogenesis [8].
Given that successful bone requires precise coordination between multiple cell types, we 
designed a series of studies to assess the ability of FTY720-coated allografts to direct the in 
situ fate of marrow-derived cells in a rat critical-sized segmental tibial defect model. We 
used a rat bone marrow chimera model that is derived from transplantation of bone marrow 
cells harvested from transgenic eGFP-expressing animals into lethally irradiated wild type 
(WT) animals. The use of rat bone marrow chimeras is particularly advantageous in that 
GFP+ hematopoietic cells are stably retained in vivo and easily monitored using 
fluorescence microscopy without the need for histochemical staining or in situ hybridization 
[23]. Consequently, the eGFP rat chimera has been used for investigating the 
multipotentiality and migration of bone marrow-derived cells in a number of different 
models, including tendon repair, bladder regeneration, and adipose tissue [23–25]. However, 
bone repair, in which the rat model offers a significantly better representation of human 
physiology than parallel mouse models, has not been investigated in rat bone marrow 
chimeras. Consequently, we investigated the relative contributions of the blood and bone 
marrow to bone repair using transgenic-based labeling of hematopoietic cells and assessed 
the fate of cells infiltrating in response to volumetric bone loss.
2. Materials and methods
2.1. Chimera creation
33 8-week old female eGFP−/− Sprague Dawley (SD) rats received transgenic bone marrow 
transplantation from 11 Sprague Dawley-eGFP (SD-eGFP) male rats (Rat Resource & 
Research Center, University of Missouri, Columbia, MO). The host rats were irradiated at 
10 grays using a Sheperd Mark 1 irradiator. Within a two-hour window immediately post-
irradiation, each animal received an intravenous tail injection of 500,000 bone marrow cells 
suspended in 1 mL of serum-free media. Host rats received equal portions of bone marrow 
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aspirate from each donor SD-eGFP rat. The rats were given the antibiotic Enrofloxacin 
(trade name Baytril, Bayer Corporation, Germany) for two weeks post-bone marrow 
transplant and carefully monitored for 21 days; weight loss of greater than 10% resulted in 
the animal being euthanized. At 6 weeks post-bone marrow transplant, 30 chimeric rats were 
randomly assigned to experimental groups in the tibial defect study.
2.2. Assessment of rat chimerism
Blood was collected from WT, eGFP, and chimeric rats via the tail vein. Red blood cells 
were lysed using Ammonium Chloride Solution (Stem Cell Technologies). The cells were 
then stained with CD11b, CD29, CD45, and CD90 (Abcam) antibodies for 1 h at 4 °C. After 
1 h, the cells were fixed with 2% PFA solution for 30 min and then re-suspended in 10% 
fetal bovine serum (FBS), and stored in 4°C prior to analysis by flow cytometry.
2.3. Allograft coating
Tibial bone was harvested from 3-month old SD male rats and cut length-wise into 4 mm-
long segments for use as allografts in tibial defects. The grafts were stripped of soft tissue, 
cleaned with detergent, hydrogen peroxide and ethanol sonication washes and then allowed 
to dry [26]. The cleaned allografts were divided into 3 groups: allograft alone, graft with 
polymer coating, graft with FTY720-loaded polymer coating. The polymer coating used 
50:50 poly(lactic-co-glycolic acid) (PLGA, 69.85 kDa, Lakeshore Bio-materials) dissolved 
in methylene chloride at a polymer to solvent ratio of 1:12 (wt:wt). For the drug-loaded 
group, FTY720 (343.9 Da, Cayman Chemical) was agitated until dissolved in the polymer 
solution at 1:200 drug to polymer ratio (wt:wt). The allograft segments were vortexed in the 
FTY720-polymer solution for 10 min. To dry the coating, allografts were stored at 4 °C 
overnight and then lyophilized for 24 h to remove the remaining solvent. We have 
previously demonstrated that this coating technique enables sustained delivery of FTY720 
for at least two weeks in vitro [27] and that the drug remains bioactive [22].
2.4. Rat tibial defect surgery
All animal surgeries were performed in accordance with an approved protocol from the 
University of Virginia Animal Care and Use Committee. 30 chimeric rats were randomly 
assigned to three different experimental groups (n = 10): allograft alone, graft with polymer 
coating, graft with FTY720-loaded polymer coating. Rats were anesthetized with isoflurane 
gas prior to and during surgery. Prior to surgery, the left hind limb was shaved and sterilized 
with betadine and 70% ethanol. A small incision was made longitudinally over the midshaft 
of the tibia. Subperiosteal dissection was made after the subcutaneous tissue was dissected 
over the anterior aspect of the tibia. Once the bone is exposed, a rotating saw (Dremel 
400XPR) was used to make a 4 mm defect distal to the tibial tubercle. The allograft segment 
was then inserted into the defect and fixed in position using a 22 gauge needle inserted into 
the intramedullary canal from the proximal end of tibia, through the allograft, and into the 
distal end of tibia. Ketoprofen was administered subcutaneously at 3 mg/kg doses 
immediately post-surgery and every 24 h thereafter for up to 72 h. Rats were given free 
access to food and water and monitored for abnormalities and complications. At 2 weeks 
post-surgery, 3 rats randomly selected from each experimental group were euthanized by 
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injection of 0.5 mL Nembutal into the heart. The left tibial bone was harvested for 
subsequent histological analysis.
2.5. X-ray and microCT analysis
Radiography was performed at week 0 and week 4 post-surgery. Rats were anesthetized by 
intraperitoneal (IP) injection with a cocktail of ketamine HCl (60 mg/kg) and xylazine (5 
mg/kg) and then placed on top of an X-ray film inside the X-ray machine (90 s, 30 V 
exposure). Yohimbine was given afterward by IP injection to reverse anesthesia. At the end 
of the study period (8 weeks post-surgery), rats were euthanized and the tibial bones were 
harvested from each rat. The soft tissue surrounding the left tibia and the intermedullary 
fixation needle were removed prior to analysis using micro-computed tomography 
(microCT) with a VivaCT40 scanner (SCANCO Medical) using the following parameters: 
38 μm voxel size, 55 kVp, 145 μA, medium resolution, 40.9 mm diameter field of view, and 
200 ms integration time (73 mGy radiation per scan). After microCT scanning, the tibiae 
were stored at −20 °C before undergoing mechanical testing. For quantification of microCT 
images, a scoring system was developed to assess the extent of integration between host and 
allograft bone. For each two-dimensional microCT image, a bridging score between 0 and 4 
was assigned. A blinded observer determined whether bridging had occurred in each of four 
pre-defined regions of interest. For each region, a binary score of ‘0’ or ‘1’ was assigned, 
with ‘1’ indicating the occurrence of bridging within that region. The four values (0 or 1) 
were tallied and an overall bridging score was assigned to each animal, with a maximum 
score of 4 possible. Subsequently, the minimum distance between the host and donor bone 
was quantified in each region of interest using ImageJ software, with all bridges being 
assigned a value of ‘0 mm’ to indicate that no space exists between host and donor bone.
2.6. Assessment of cell proliferation
MSCs were isolated from WT and chimeric SD rats and seeded in culture plates under 
growth media (α-MEM, 15% FBS, 1% Penicillin–Streptomycin (PS), 1% L-Glutamine) 
with 0, 0.15 nM or 15 nM FTY720. These concentrations were selected because low dose 
FTY720 (below 100 nM) was previously demonstrated to promote osteogenic differentiation 
of C2C12 myoblasts [17]. After 10 days of culture, cells were fixed with 10% formalin and 
subsequently stained with crystal violet. Subsequent imaging was performed using an 
upright microscope at 10× magnification and colony formation was measured by quantifying 
the number of pixels above a pre-determined threshold.
2.7. Alizarin red staining
MSCs harvested from WT and chimeric SD rats were seeded in culture plates and grown in 
growth media (DMEM F12, 10% FBS, 1% PS) for 3 days. The MSCs were then cultured 
under osteogenic differentiation media (DMEM-Low Glucose, 10% FBS, 1% PS, 100 nM 
Dexamethasone, 10 mM Beta-glycerol phosphate, 2 mM L-Glutamine) and 0.15 nM or 15 
nM FTY720. After 10 days, the cells were fixed with 10% formalin and stained with 
Alizarin Red S Solution (2% w/v; pH 4.2). The plates were evaluated by light microscopy 
and mineralization was measured by quantifying the pixel intensity.
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2.8. Tartrate-resistant acid phosphatase staining
The RAW264.7 murine macrophage cell line was used to assess the effect of FTY720 on 
osteoclastogenesis. Cells were seeded on a coverslip in a culture plate and cultured in 
growth media (α-MEM, 10% FBS, 1% PS) with 50 ng/ml murine sRANKL and 0.15 nM or 
15 nM of FTY720. Following 5 days of culture, tartrate-resistant acid phosphatase (TRAP) 
staining was carried out according to the manufacturer’s instructions (Leukocyte TRAP 
Staining Kit 387A, Sigma Aldrich). Stained cells were counter-stained with Hematoxylin 
and imaged on an upright microscope.
2.9. Mechanical testing
At 8 weeks post-surgery, tibiae were extracted and wrapped in PBS-soaked gauze for 
storage at −20 °C until mechanical testing was performed. Immediately prior to testing, 
samples were thawed and any residual soft tissue was removed. The distal end of the tibia 
was trimmed to center the defect in the sample. The proximal and distal ends of the tibia 
were then embedded in end blocks using Wood’s metal (Alfa Aesar) and aligned using a 
custom fixture. The sample was loaded into holding brackets mounted on a Bose 
ElectroForce System (ELF 3200, Bose Endura TEC) fitted with a 2 Nm loading cell. 
Keeping the proximal end fixed, the distal end was rotated at 3° per second until fracture. 
Torque and rotation were recorded. Maximum torque was determined by locating the failure 
torque.
2.10. Immunohistochemical analysis
Animals from each treatment group were euthanized at 8 weeks, and the tibiae were 
extracted. Samples were decalcified and embedded in paraffin and 5 μm sections were 
prepared. Prior to staining, sections were deparaffinized and antigen retrieval was performed 
at 95 °C with 10 mM citrate buffer for 8 min. Sodium borohydride solution (100 mg/mL) 
was used to reduce background autofluorescence of the tissue. Samples were permeabilized 
with 0.2% Triton X-100 and then blocked using 10% donkey and goat serum to prevent non-
specific antibody binding. Immunofluorescence staining was performed using anti-GFP 
(Abcam), anti-Osteocalcin (Abcam), anti-alpha Smooth Muscle Actin (Abcam), isolectin 
IB4 (Life Technologies), anti-CCR7 (Abcam), CD206 (Bioss), or CD90 (BioLegend). 
Samples were incubated with primary antibody overnight at 4 °C, and secondary antibody 
for one hour at room temperature. Slides were mounted in 100 mM glycine and images were 
taken on the Zeiss LSM 700 confocal microscope using Zen software (Zeiss). Quantification 
of immunohistochemistry was performed by counting the number of cells positive for the 
specified markers by identifying a threshold based on secondary only controls. For 
identification of newly formed bone, sections were stained with hematoxylin and eosin and 
then imaged for autofluorescence using an upright microscope.
3. Results
3.1. Development and characterization of eGFP rat chimeras
To gain insight into how circulating cell populations contribute to allograft incorporation in 
a critical sized rat tibial defect model, we generated chimeric rats expressing eGFP in the 
bone marrow compartment. eGFP−/− SD rats were lethally irradiated and transplanted with 
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bone marrow derived from eGFP+/− litter mates, resulting in 100% survival of all transplant 
recipients (Fig. 1A). Flow cytometry analysis revealed that 75% of circulating white blood 
cells were GFP+ cells (Fig. 1B). Additionally, chimeric rats demonstrated reconstitution of 
CD11b+, CD29+, CD45+, and CD90+ lineages in blood at 4 weeks post-transplantation (Fig. 
1C), signifying successful and stable transplantation with GFP+ bone marrow.
Bone marrow stromal cells from chimeric rats remain primarily uncharacterized in their 
proliferative and differentiation capacities. We compared colony formation and osteogenic 
differentiation of MSCs derived from WT and chimeric rats. Chimeric MSCs formed larger 
colonies that covered 5-fold more area and demonstrated a 5-fold increase in average size 
compared to WT MSCs (Fig. 1D), without impacting the overall colony number. MSCs 
from chimeric rats more highly stained with Alizarin Red, indicating that chimeric MSCs 
generate more mineralized matrix in vitro (Fig. 1E). This likely results either from an overall 
increase in the number of cells capable of mineralization or an increase in the average output 
per cell. These findings highlight an important difference in the behavior of MSCs derived 
from rats undergoing hematopoietic reconstitution with cells derived from eGFP+/− rats that 
should be considered when designing experiments that investigate the role of bone marrows 
cells in chimeric rats.
3.2. Bone growth and allograft incorporation in a long bone defect model
Critical sized segmental defects (4 mm) were generated in the tibiae of chimeric rats 6 
weeks after lethal irradiation and bone marrow transplantation. Allograft incorporation was 
monitored at weeks 0 and 4 by X-ray and week 8 by ex vivo microCT scans. X-ray imaging 
indicates that animals treated with FTY720-coated allografts show better graft integration 
and callus formation as early as 4 weeks (Fig. 2A). MicroCT images taken at week 8 
indicate that this leads to new mineralized bone formation and better healing in animals 
treated with grafts coated with FTY720 (Fig. 2B). In particular, the interface between donor 
and host bone is less distinct in animals receiving FTY720, indicating improved allograft 
incorporation. We scored the extent of bridging that occurred between allograft and host 
bone in two-dimensional microCT renderings and found that FTY720 significantly increases 
bridging relative to both uncoated and PLGA-coated grafts (Fig. 2C). Additionally, FTY720 
reduces the overall distance between host and donor bone compared to uncoated controls 
(Fig. 2D). H&E staining of tibiae longitudinally sectioned through the defect site also show 
more bone formation and better graft integration in animals treated with FTY720-coated 
allografts compared to controls (Supplemental Fig. 1).
In the case of load-bearing bone repair, newly-deposited bone must be able to support the 
mechanical load exerted by the rest of the body. We used torsional testing to measure the 
magnitude of forces sustained by newly-healed bone. While we experienced significant 
sample variability in mechanical testing, inspection of the force–displacement curves shows 
that FTY720-treated grafts exhibited mechanical properties more similar to uninjured 
contralateral bones (Fig. 2E). Across all tested samples, FTY720 best restores the strength of 
native bone, as the torque at failure is most similar to contralateral controls (Supplemental 
Fig. 2). No significant differences in stiffness between all groups were observed.
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3.3. S1P signals regulate osteogenic processes
Given that polymer coatings releasing FTY720 promote allograft incorporation and 
mineralization, we assessed the presence of osteocalcin-positive (OC+) cells at the interface 
between allograft bone and host tissue. FTY720-coated allografts have a higher frequency of 
OC+ cells in the surrounding tissue than uncoated or PLGA-coated allografts as detected by 
immunohistochemistry (Fig. 3A, B). Additionally, in animals receiving FTY720, OC+ cells 
infiltrated void areas within the graft and closely associated with donor bone, enabling bone 
deposition at the graft surface. Fluorescence measurements of histological sections, in which 
new bone autofluoresces more brightly, indicate a greater amount of newly-formed bone in 
animals receiving FTY720 allografts (Supplemental Fig. 1). New bone formation is the 
cumulative result of a delicate balance between osteoblast deposition of mineralized matrix 
and osteoclast resorption of damaged bone. Consequently, we investigated the effect of S1P 
receptor signaling on both osteoblastic and osteoclastic behaviors in vitro. Low dose 
FTY720 appears to minimally impact colony formation of MSCs, as total colony coverage 
only slightly increased (Fig. 3C) and colony number was not impacted by the presence of 
0.15 nM or 15 nM FTY720. The osteogenic capacity of MSCs appears to be enhanced by 
S1P signals, as the intensity of Alizarin Red staining increased in the presence of FTY720 
and this was associated with a modest increase in the total percentage of mineralized regions 
(Fig. 3C and D). To study the effect of FTY720 on osteoclastogenesis, we treated 
RAW264.7 macrophages with RANKL and stained for TRAP. Low (0.15 nM) and high (15 
nM) dose FTY720 increased osteoclastic differentiation, with the lower dose having the 
greatest effect (Fig. 3E). Taken together, these results indicate that FTY720 released from 
degradable allograft coatings likely alters the fate of osteoblastic and osteoclastic precursors 
in the peri-implant tissue.
3.4. FTY720 promotes vascular maturation in healing bone
We have previously demonstrated that local delivery of FTY720 increases the formation of 
vascular networks in remodeling bone after injury [19,22]. Here, the dynamics of FTY720’s 
effects on vascular ingrowth into transplanted allografts were assessed by visualizing lectin+ 
microvessels and mature SMA+ blood vessel formation after bone injury. At 2 weeks post-
injury, SMA+ cells were primarily unassociated into vascular structures and were prominent 
in the tissue surrounding the graft (Fig. 4A). By week 8, the interfacial tissue appeared much 
more highly vascularized, with the appearance of lectin+ microvessels and large smooth 
muscle-coated SMA+ vessels having a diameter greater than 100 μm (Fig. 4B and C). 
Groups receiving FTY720 appear to have more lectin+ and SMA+ blood vessels 
surrounding the allograft and more SMA+ cells infiltrating donor bone at week 8 post-injury 
(Fig. 4B and C). Interestingly, these group differences were not observed in week 2 
histological sections, indicating that FTY720 likely affects the maturation of nascent 
vasculature formed during early wound healing processes. FTY720 had a more robust effect 
on SMA+ blood vessels than lectin+ vessels, further supporting the hypothesis that FTY720 
promotes vascular maturation. Moreover, FTY720’s effect on vascularization in and around 
implanted allografts likely contributes to improved allograft incorporation and bone 
regeneration.
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3.5. Fate of bone marrow-derived cells during bone regeneration
The precise role of circulating and resident cell populations, including inflammatory cells 
and mesenchymal progenitors, to bone healing remains unclear. While it is apparent that 
infiltrating inflammatory cells likely participate in repair processes, the relative 
contributions by blood and tissue compartments has not been characterized. To assess the 
frequency of bone marrow-derived cells that becomes M1-like or M2-like macrophages, 
histological sections stained with anti-GFP antibody were counterstained for CCR7 (for M1-
like macrophages) or CD206 (for M2-like macrophages) expression (Fig. 5A). We 
quantified the ratio of GFP+CD206+ to GFP+CCR7+ cells to investigate whether FTY720 
alters the fate of bone marrow-derived inflammatory cells. At 2 weeks post-injury, we 
measured a 30% increase in the ratio of GFP+CD206+ to GFP+CCR7+ cells, suggesting 
that FTY720 changes the phenotype of recruited macrophages (Fig. 5B). Additionally, in 
animals not receiving FTY720, CD206+ cells appear to be excluded from the tissue space 
that is immediately adjacent to implanted grafts, likely reducing their ability to guide repair 
processes and graft integration. GFP+ cells represent cells derived from transplanted bone 
marrow and thus correlate to circulation-derived cells or tissue-resident cells that were 
replenished by circulating cells during the 6-week pre-surgery period of hematopoietic 
reconstitution. Consequently, GFP-negative cells signify populations that were protected 
from irradiation, likely consisting of embryonically-derived tissue resident immune cells, 
stromal and parenchymal cells, and a small frequency (20–30%) of non-GFP+ circulating 
cells (Fig. 1B). GFP+ cells infiltrated the interfacial tissue space surrounding allografts, with 
a subset of cells also expressing CCR7 or CD206 (Fig. 5A, white arrows). Quantification 
across all animal groups indicates that CCR7+ M1-like macrophages encompass a larger 
frequency of GFP+ cells (30%) than CD206+ M2-like macrophages (20%), indicating that 
at 2 weeks post-injury, bone marrow-derived cells have a greater probability of adopting an 
inflammatory phenotype (Fig. 5C). Interestingly, the GFP+ population makes up an equal 
proportion of CCR7+ and CD206+ cells (Fig. 5D). These results indicate that both a 
circulating and a tissue resident, irradiation-resistant population contribute to the 
inflammatory cell profile during early stage bone regeneration and FTY720 may promote 
tissue repair by shifting the phenotype of recruited macrophages to a pro-regenerative M2-
like profile.
Monocyte-derived macrophages represent a population of blood- and bone marrow-derived 
progenitor cells that play critical roles in dictating the capacity of an injury to heal. In the 
context of bone repair, these cells participate in crosstalk with osteoblasts and mesenchymal 
progenitors, as well as vascular endothelial cells [8]. Consequently, we assessed whether 
progenitor cells surrounding allograft implants express GFP. In all treatment groups, CD90+ 
cells that co-stained for GFP were observed in sections taken at week 2 post-injury, 
indicating that a subset of these progenitor cells originates from bone marrow (Fig. 6D). 
Moreover, we were interested in whether more mature osteoblastic cells were derived from 
the bone marrow compartment. Interestingly, we observed cells that stained positive for both 
OC and GFP, indicating that a fraction of OC+ osteoblastic cells are derived from the bone 
marrow compartment 8 weeks after injury (Fig. 6A). FTY720 does not appear to affect the 
absolute number of GFP+OC+ bone marrow-derived osteoblatic cells in the tissue 
surrounding allograft (Fig. 6B); however, the proximity of these cells to the graft and 
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intensity of osteocalcin staining is enhanced in FTY720 animals (Fig. 6A). Quantification of 
histological sections from all groups indicated that as many as 25% of OC+ cells were 
derived from bone marrow (Fig. 6C). While this is much lower than the contribution of WT 
cells to the OC+ population in healing bone, this data indicates that there is likely a 
significant role for osteogenic progenitor cells derived from bone marrow in healing bone.
4. Discussion
The precise role of bone marrow- and circulation-derived progenitor cells in bone healing 
remains poorly understood, and thus the design of strategies that exploit the relative 
contributions of these cells has been limited. Peripheral blood mononuclear cells encompass 
a heterogeneous cell population containing many different cell types that may participate in 
bone healing, including monocytes/macrophages, neutrophils, endothelial progenitor cells, 
and osteogenic progenitor cells. Elucidation of the respective roles for various tissue 
compartments in bone repair is critical for designing novel therapeutics that harness these 
cell populations to promote healing. The current work systematically examines the 
contributions of GFP+ cells that are derived from reconstituted bone marrow during healing 
of critical-sized tibial defects in chimeric rats and examines whether lipid-based therapies 
can improve post-trauma functional recovery of damaged bone by directing progenitor cell 
fate.
Macrophages represent a multi-faced population of cells that differ in recruitment kinetics 
and function in a wide range of injury contexts. These cells are required for efficient bone 
repair, as systemic depletion of macrophages with clodronate liposomes significantly 
impairs tibial defect healing [28]. Macrophages exhibit a wide range of diverse phenotypes 
that have been primarily categorized into “classically activated” M1 macrophages, which 
possess pro-inflammatory, phagocytic, and proteolytic functions essential for removal of 
damaged tissues, and “alternatively activated” M2 macrophages, which are anti-
inflammatory and participate in tissue regeneration, angiogenesis, and matrix synthesis [29]. 
In vivo, injury-responsive macrophages are extremely heterogeneous, existing along a 
spectrum of phenotypes, with the M1 and M2 phenotypes representing opposite extremes. 
An additional level of complexity exists due to the fact that macrophages present at 
inflammatory sites may be derived from either circulation or tissue resident macrophage 
pools that are embryonically-derived and self-renewing during homeostasis [30].
Our data indicates that bone marrow-derived GFP+ cells are more likely to become CCR7+ 
than CD206+ at 2 weeks post-injury (Fig. 5C). The kinetics of specific macrophage 
phenotypes is not well-characterized, particularly in the context of bone repair. However, the 
current work indicates that specification down an M1-like lineage is more prominent during 
early bone repair, suggesting that the characteristic pro-inflammatory phase may be 
extended beyond a couple of days to several weeks during bone healing. Interestingly, GFP+ 
cells contribute equal proportions to both CCR7+ and CD206+ populations (Fig. 5D), likely 
indicating that the injury microenvironment is the primary determinant of macrophage 
phenotype, as there is no difference in the fate of either recruited or tissue resident 
populations. We have previously reported that local delivery of FTY720 skews the 
inflammatory profile to generate a pro-regenerative injury niche, both in soft tissue and 
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craniofacial bone [18,19]. In particular, FTY720 increases the frequency of anti-
inflammatory M2 macrophages both at early (3 days) and later (3 weeks) time points, which 
facilitates neo-vascularization and tissue repair. In the current work, FTY720 increased the 
ratio of GFP+ M2:M1 macrophages at 2 weeks post-injury, which likely leads to 
improvements in vascularization and allograft bridging observed by 8 weeks (Fig. 5B). 
FTY720 more robustly induced the formation of SMA+ mature blood vessels than lectin+ 
vessels around implanted allografts (Fig. 4B and C), indicating that FTY720 likely promotes 
vascular maturation, which could be initiated by pro-arteriogenic macrophages. 
Additionally, myeloid cells are a key player in coupling osteogenesis to angiogenesis [8] and 
the precise ratio of M2:M1 macrophages likely dictates the ability of injured tissue to 
regenerate [31,32].
While the occurrence of myeloid cell infiltration from the blood during bone repair is well-
documented, the existence and role of circulating osteogenic progenitor cells is less 
understood. Peripheral blood cells that express osteogenic markers such as osteocalcin or 
alkaline phosphatase have been detected both in murine and human samples [33,34]. In 
studies using parabiotic mice in which a WT and a chimeric mouse containing GFP-labeled 
bone marrow were conjoined, BMP-2-laden pellets were subcutaneously implanted. OC+ 
GFP+ cells were found at surrounding ectopic bone in the WT mouse [35] and in similar 
parabiotic studies using a fracture model, indicating the existence of circulation-derived 
GFP+ bone-forming cells. Additionally, administration of compounds that increase the 
frequency of osteogenic progenitor cells in circulation such as the CXCR4 inhibitor 
AMD3100, increases ectopic bone formation [36] and improves fracture healing [37]. These 
results indicate that bone marrowand circulation likely contribute to bone repair, but the 
precise contribution may be context-dependent, where both the size and location of injury 
are important. In the present work, we observed that the bone marrow compartment 
significantly contributes to the pool of tissue OC+ cells, with as many as 25% being GFP+ 
at week 8 post-injury (Fig. 6C). The source of these cells is not clear and could derive from 
circulating osteogenic cells or contiguous marrow that migrates in response to injury-
induced chemotactic cues [6]. It is likely that at least a population of these cells were derived 
from a pool of GFP+CD90+ progenitor cells that appeared at the injury site at week 2 post-
surgery (Fig. 6D). The reported mechanisms of OC+ cell infiltration appear to be conserved 
across multiple types of bone injury, as fracture healing also induces bone marrow-derived 
OC+ cell infiltration [38]. FTY720 localizes OC+ cells to the graft surface (Fig. 3A), which 
may be through enhanced recruitment of progenitor cells, as we have previously reported 
that local FTY720 increases tissue levels of chemokines such as SDF-1 and RANTES [18].
Healing damaged bone is a function of both the amount of osteogenic cells active within the 
defect area, as well as the osteogenic capacity of each individual cell. While allografts 
provide a scaffold for cell and tissue ingrowth into the defect area, non-union remains a 
major concern, in part due to insufficient infiltration of osteogenic cells. Consequently, 
small molecule-based approaches for increasing the recruitment and differentiation of bone-
forming cells represents a viable and translational approach for improving allograft 
functionality [39]. In this study, we show that in addition to an increase in the frequency of 
OC+ cells at the allograft integration site, the osteogenic capacity of MSCs is also elevated 
after FTY720 treatment (Fig. 3B). The osteogenic effects of FTY720 enabled newly formed 
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bone to sustain higher torsional forces and exhibited a deformation pattern similar to that 
sustained by native, unbroken bone (Fig. 2E).
The current work advances our understanding of the role that bone marrow-derived 
progenitor cells play in bone regeneration and allograft incorporation. While cell infiltration 
from blood and bone marrow are likely context- and time-dependent, a significant 
contribution to both osteogenic and inflammatory cell populations from irradiation-sensitive 
hematopoietic tissues was observed. The development of novel strategies to improve clinical 
bone reconstruction and regeneration will likely depend on an understanding of endogenous 
mechanisms of cell recruitment and their in situ roles in repair. Therapies derived from 
engineering progenitor cell migration within the injury microenvironment represent a 
promising and powerful approach for bone repair.
5. Conclusions
Development of tissues that fully interface with damaged host tissue remains a significant 
challenge for the field of tissue engineering. Allografts, which recapitulate some of the 
structure and function of native bone, would likely have a better clinical outcome if coupled 
to strategies that specifically guide endogenous cell recruitment. The current work 
demonstrates that bone marrow-derived progenitor cells infiltrate rat critical sized bone 
defects and significantly contribute to inflammatory and bone-forming cell populations. 
Bioactive allograft coatings containing FTY720 improve graft vascularization, bone 
formation, and integration with host tissue, likely through local immune modulation that 
improves angiogenic–osteogenic coupling. Future strategies for engineering bone 
regeneration will likely rely on an understanding of endogenous mechanisms of repair to 
identify therapeutic targets and maximizing cellular contributions.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Rat bone marrow chimeras as a model for studying bone regeneration. (A) Sprague–Dawley 
rat bone marrow chimeras were generated by transplanting eGFP+ bone marrow into 
lethally irradiated eGFP−/− rats. Tibial defects were created 6 weeks post-transplantation. 
(B) Flow cytometry analysis of eGFP expression in blood 4 weeks post-bone marrow 
transplantation demonstrated stable reconstitution of the hematopoietic system with GFP+ 
cells, n = 3–4. (C) GFP+ cells display multi-lineage differentiation as assessed by flow 
cytometry analysis of blood taken 4 weeks post-transplantation, n = 3. (D) Bone marrow 
from chimeras after 7 days of culture as observed with crystal violet staining (left) and 
quantification of colony coverage (right), n = 6. (E) Bone marrow from eGFP chimeras after 
7 days of culture in osteogenic media as observed with Alizarin red staining (left) and 
quantification of mineralized area (right), n = 3. Scale bar, 100 μm; *p < 0.05. (For 
interpretation of the references to colour in this figure legend, the reader is referred to the 
web version of this article.)
Das et al. Page 16














FTY720-coated allografts promote bone formation and graft incorporation. (A) 
Representative X-rays of tibiae indicate the FTY720 improves integration between host and 
donor bone by week 4 post-injury. (B) Representative microCT reconstructed images taken 
at 8 weeks post-injury indicate that FTY720 increases bone deposition around implanted 
allgorafts (top row: 3D images, bottom row: 2D cross-sectional images). (C) FTY720 
increases the bridge score assessed in 2D microCT images compared to uncoated and 
PLGA-coated allograft controls, n = 4–5. (D) FTY720 decreases the distance between host 
and donor bone compared to uncoated allografts, n = 4–5. (E) Representative torque plots 
from torsional mechanical testing of tibiae explanted 8 weeks post-injury indicate that 
FTY720 allografts better recapitulate the mechanical properties of uninjured contralateral 
control bone, n = 3–4. Scale bars, 500 mm; *p < 0.05.
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FTY720 promotes osteogenesis and osteoclastogenesis. (A) Histological sections from tibiae 
explanted at week 8 post-injury and immunostained with anti-osteocalcin (OC) and DAPI 
demonstrate that FTY720 increases the frequency of OC+ cells and their proximity to the 
graft, n = 2–3. Scale bars, 100 μm; white arrows, OC+ cells; dotted line, graft edge. (B) 
Quantification of histological sections stained with OC, n = 2–3. (C) Bone marrow from 
wild type animals cultured for 7 days in the presence of low (0.15 nM) and high (15 nM) 
dose FTY720 and stained with crystal violet (top) or Alizarin red (bottom). (D) 
Quantification of colony cell coverage (left) or amount of mineralization (right) shows that 
FTY720 minimally impacts colony size, but increases mineralization of MSCs, n = 3–6. (E) 
FTY720 promotes osteoclastogenesis as assessed by TRAP staining of RAW264.7 cells 
cultured for 5 days in RANKL and low or high dose FTY720. (For interpretation of the 
references to colour in this figure legend, the reader is referred to the web version of this 
article.)
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FTY720 increases the number of α-SMA+ blood vessels surrounding allografts. (A) 
Histological sections from tibiae explanted and immunostained with anti-α smooth muscle 
actin (SMA) and DAPI show that few mature blood vessels are present around allografts in 
all groups at 2 weeks post-injury. (B) FTY720 promotes formation of lectin+ microvessels 
by 8 weeks post-injury, n = 2–3. (C) FTY720 promotes formation of mature smooth muscle-
coated blood vessels by 8 weeks post-injury, n = 2–3. Scale bars, 100 μm; dotted line, graft 
edge. *p < 0.05.
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The phenotype of bone marrow-derived macrophages is altered by FTY720. (A) 
Histological sections from tibiae explanted at week 2 post-injury and stained with anti-GFP, 
DAPI, and CCR7 (top row) or CD206 (bottom row). Scale bars, 50 μm; white arrows, GFP
+CCR7+ or GFP+CD206+ cells; dotted line, graft edge. (B) FTY720 increases the ratio of 
CD206+GFP+ to CCR7+GFP+ cells at 2 weeks post-injury, n = 2–3. (C) Quantification of 
the percentage of CCR7+ and CD206+ cells within the total GFP+ cell population 
demonstrates that across all groups, GFP+ bone marrow-derived cells are more likely to 
become CCR7+ than CD206+ at 2 weeks post-injury, n = 7–8. (D) Quantification of the 
percentage of total CCR7+ and CD206+ cells that also express GFP demonstrates that 
across all groups, the bone marrow contributes equal proportions to both CCR7+ and 
CD206+ cells at 2 weeks post-injury, n = 7–8. *p < 0.05.
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Bone marrow contributes to mature bone-forming cells and osteogenic progenitor cells. (A) 
Histological sections from tibiae explanted at week 8 post-injury and stained with anti-GFP, 
OC, and DAPI. White arrows, GFP+OC+ cells; dotted line, graft edge. (B) FTY720 does not 
impact the number of GFP+OC+ cells in histological sections imaged around the graft, n = 
2–3. (C) Across all groups, GFP+ bone marrow-derived cells contribute significantly less 
(about 25%) than unlabeled wild type (WT) cells (about 75%) to OC+ populations detected 
8 weeks post-injury, n = 7. (D) Histological sections from tibiae explanted at week 2 post-
injury and stained with anti-GFP, anti-CD90, and DAPI. White arrows, GFP+CD90+ cells. 
Scale bars, 50 μm; *p < 0.05.
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